Abbott realigns top management

Abbott Laboratories is opting to reshuffle executive responsibilities rather than filling its No. 2 management slot. The COO title will disappear when current COO Richard Gonzalez retires next month. Instead of hiring a new COO, the chiefs of the company's four top operating units--medical devices, pharmaceuticals, nutritionals and diagnostics--will report directly to Abbott CEO Miles White.

The company's division head for pharma will be new to the reins, too. Executive Vice President James Tyree is replacing Abbott veteran Bill Dempsey, who's also retiring, in that post.

- read the report from The Chicago Tribune

Related Article:
Abbott deal puts focus squarely on pharma. Report

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.